Section Arrow
Quote
PRTC.NASDAQ
- PureTech Health plc
Quotes are at least 15-min delayed:2026/01/02 04:49 EST
Pre Market
Last
 --
-- (--)
Bid
17.17
Ask
17.89
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 --
-- (--)
Day High 
-- 
Prev. Close
16.64 
1-M High
18.05 
Volume 
189 
Bid
17.17
Ask
17.89
Day Low
-- 
Open
-- 
1-M Low
16.01 
Market Cap 
402.16M 
Currency 美元 
P/E 9.79 
%Yield -- 
10-SMA 16.87 
20-SMA 16.76 
50-SMA 17.02 
52-W High 20 
52-W Low 13.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.70/-4.83
Enterprise Value
416.83M
Balance Sheet
Book Value Per Share
15.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
4.32M
Operating Revenue Per Share
0.07
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
Pre Market 0.444 +0.0273 +6.55%
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
Pre Market 0.6701 -0.9099 -57.59%
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
Pre Market 8.86 +0.04 +0.45%
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
Pre Market 4.135 +0.365 +9.68%
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Pre Market 0.2282 +0.0033 +1.47%
Industry overview quotes are at least 15 minutes delayed
Business Description
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, whichderives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.